Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Dayra Therapeutics

Request full access

Oral macrocyclic peptide therapeutics for various diseases

San Francisco, United StatesFounded 2024Biotech & Life Sciences

About Dayra Therapeutics

Dayra Therapeutics is a biotechnology company launched in 2024, focused on developing oral macrocyclic peptide therapeutics to treat a range of serious diseases. The company was founded by the venture capital firm Versant Ventures, emerging from its Frontier Discovery Engine, a research and development incubator located in Toronto and Montreal. Dayra's leadership includes Rami Hannoush, Ph.D., a venture partner at Versant, serving as acting CEO, and Roger Palframan, Ph.D., as Chief Scientific Officer.

The company's core technology combines a macrocycle discovery platform with computational design and modeling. This approach aims to create novel, orally administered macrocyclic peptides that can selectively target disease-relevant proteins. This class of medicine has the potential to offer the high specificity and efficacy of biologic drugs, which are typically injectable, but with the convenience of an oral pill. The technology is designed to access protein binding sites that are challenging for traditional small molecule drugs to reach.

Upon its launch, Dayra Therapeutics secured over $70 million in committed capital. A cornerstone of its initial financing is a major research collaboration with Biogen Inc. Under this partnership, Biogen provided a $50 million upfront payment for Dayra to identify, validate, and optimize oral macrocycle candidates for high-priority immunological targets. The business model involves Biogen advancing these molecules through further development, manufacturing, and potential commercialization. Biogen holds the option to acquire each development candidate, which would trigger additional payments to Dayra, along with potential preclinical and clinical development milestones for each program.

Source: Dealroom company data

At a glance

Status
Operational
Employees
9
Open positions
None listed
Dealroom signal
24.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Drug Development, Immune System, Biotech and Pharma, AI Drug Discovery, CompBio, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Nov 2025 $70M $280M Versant Ventures ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Dayra Therapeutics website traffic

Latest recorded traffic for Dayra Therapeutics is 300 monthly website visits, down 6.3% over the last three months.

Latest monthly visits300 3-month web change-6.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Dayra Therapeutics in the San Francisco ecosystem

Live from Dealroom

The Dayra Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

Employees 9 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States87.5%
🇩🇪 Germany12.5%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Dayra Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Dayra Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.